Summary: An animal study suggests that setmelanotide might improve breathing by acting on brain circuits that control respiration, offering a potential new approach for obesity hypoventilation syndrome but requiring much more research.
Key takeaways:
- Obesity hypoventilation syndrome leads to chronic underbreathing and carbon dioxide buildup, with limited treatment options beyond CPAP/BiPAP.
- Researchers found that setmelanotide improved breathing in obese mice beyond what could be explained by increased metabolism.
- The study identified the MC4R brain pathway as directly influencing breathing control, with setmelanotide potentially bypassing faulty leptin signaling seen in obesity.
An animal study provides promising evidence that setmelanotide, a Food and Drug Administration-approved medication for a rare genetic obesity disorder, may offer a pathway for treating obesity hypoventilation syndrome.
Limited Options for Obesity Hypoventilation Syndrome
Obesity hypoventilation syndrome commonly coexists with obstructive sleep apnea. While CPAP and BiPAP help keep airways open while sleeping, they provide limited help to people with obesity hypoventilation syndrome. People with this syndrome don’t breathe deeply or frequently enough, especially during sleep, which leads to a buildup of carbon dioxide in their bodies even when they’re awake.
“Our research addresses a critical gap in treatment options for obesity hypoventilation syndrome,” says study coauthor Vsevolod Polotsky, MD, PhD, a professor of anesthesiology and critical care medicine at George Washington University’s School of Medicine and Health Sciences, in a release. “Our findings could be the first step toward a much-needed treatment for a life-threatening condition that impacts millions.”
Highlights of Study in Obese Mice
Polotsky and postdoctoral researcher Mateus Amorim used the setmelanotide to see if it could help improve breathing in obese mice. Researchers targeted a protein found on certain neurons in the brain called MC4R pathway that helps the brain control how much mammals and humans eat, how much energy they burn, and even how they breathe.
The study found:
- Just one dose of setmelanotide improved breathing and helped the mice respond better to high levels of carbon dioxide.
- Setmelanotide improved breathing more than would be expected just from boosting metabolism, meaning it likely acts directly on brain regions that control breathing.
- When using special tools to turn on MC4R neurons, they found breathing improved. But when those same neurons were turned off, breathing got worse, even when setmelanotide was given.
- They also discovered that MC4R neurons connect directly to other brain cells that control the diaphragm.
Major Advance in Understanding
This is direct evidence that the MC4R pathway plays a critical role in how the brain controls breathing in obesity. Setmelanotide may be able to treat obesity hypoventilation syndrome by bypassing the leptin (a hormone made by fat cells that helps regulate breathing), which is common in people with obesity.
While more studies of setmelanotide for obesity hypoventilation syndrome are still needed, this research represents a major advance in understanding how the brain controls breathing in obesity.
We recommend for you:
ID 346193142 © Mukhina1 | Dreamstime.com
